Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer

Granowska, M.; Britton, K. E.; Mather, S. J.; Lowe, Donna; Ellison, David H.; Bomanji, Jamshed; Burchell, Joy; Taylor‐Papadimitriou, Joyce; Hudson, C.R.; Shepherd, J. H.

doi:10.1007/bf00175160

Cited by 11 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radioimmunoscintigraphy has been used with success in the management of some neoplasms in specific clinical conditions (Britton and Granowska, 1987;Bischof Delaloye et al, 1989;Doerr et al, 1990;Massuger et al, 1990;Wahl, 1992;Britton et al, 1993;Granowska et al, 1993), but it is limited by low tumour to background ratio, low percentage of injected dose per gram taken up by the tumour and heterogeneity of expression of the antigen. To overcome these problems, a change detection algorithm has been applied to detect small changes with time in antibody uptake.…”

mentioning

confidence: 99%

99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection

Biassoni

Granowska²,

Carroll³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

mentioning

confidence: 99%

99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection

Biassoni

Granowska²,

Carroll³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

“…Studies with flow cytometry have shown that the monoclonal antibody SM3 has a higher specificity for ovarian carcinoma than other antibodies (Van Dam et al, 1991). This led Jobling et al (1991) and Granowska et al, 1990Granowska et al, , 1993a to use SM3-radiolabelled 99Tcm as the first choice for radioimmunoscintigraphy.…”

Section: Discussionmentioning

confidence: 99%

“…Preoperative imaging by radioimmunoscintigraphy has been shown to be of benefit using a variety of radionuclides (Granowska et al, 1984(Granowska et al, , 1990Davies et al, 1985;Epenetos et al, 1985;Jackson et al, 1985;Critchley et al, 1986;Shepherd et al, 1987;Jobling et al, 1990) but is still not part of routine investigations for ovarian cancer in all specialist centres. Granowska et al (1993a), however, demonstrated that 99Tcm-labelled anti-PEM monoclonal antibodies produced a 100% sensitivity with a 73% specificty for ovarian cancer in external scanning. As a label, 99Tcm has the added advantage of a short half-life (6 h), allowing a high activity to be administered, giving a high count rate signal.…”

Section: Discussionmentioning

confidence: 99%

Peroperative radioimmunodetection of ovarian carcinoma using a hand-held gamma detection probe

Ind

Granowska²,

Britton³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

Summary Radioimmunoscintigraphy (RIS) can be used in the preoperative localisation of ovarian carcinoma to demonstrate uptake of radiolabelled monoclonal antibodies into neoplastic tissue. The tissue uptake of radiotracer was evaluated at laparotomy in 16 patients with suspected ovarian cancer who had preoperative RIS using technetium-99m-labelled monoclonal antibodies SM3 and H17E2. A gamma detection probe ('DP) was used to measure uptake in possible tumour deposits at operation and also the uptake in tissues resected for histology. The percentage uptake of the initial injected dose of radiotracer was also measured in resected tissues. Activity was found to be significantly higher in malignant than in non-neoplastic tissue by all three methods of evaluation. The yDP used peroperatively yielded a 82% sensitivity with a 72% specificity for an uptake ratio of 1.5:1. When tissue was examined immediately after resection, for a 100% specificity the sensitivity was 64%. In vitro measurements of monoclonal antibody uptake by tissue similarly gave a 65% sensitivity with a 100% specificity. Peroperative and immediate post-operative measurements of tissue radioactivity can be performed quickly and conveniently, and in some cases may be of benefit in the localisation of tumour at laparotomy and in providing extra information when tissue is examined by frozen section.Ovarian cancer has the worst prognosis of all gynaecological malignancies in the UK. It presents late and is often difficult to differentiate from benign lesions until surgery and histological examination have been performed. The surgical management of ovarian carcinoma is more complex than that of benign tumours and may be dictated by the results of histological frozen sections performed at the time of laparotomy. This is especially important in young women with unilateral ovarian tumours. In addition, a major factor determining the prognosis is whether or not there has been complete resection of the tumour. Therefore, accurate determination of the amount and extent of the tumour is essential. CT scans, pelvic ultrasound and surgical exploration, even when used together, are less than 100% accurate . However, radioimmunoscintigraphy using monoclonal antibodies against polymorphic epithelial mucin and other epitopes may yield more complete preoperative information (Granowska et al., 1984(Granowska et al., , 1990(Granowska et al., , 1993Davies et al., 1985;Epenetos et al., 1985;Jackson et al., 1985; Critchley et al., 1986;Shepherd et al., 1987;Jobling et al., 1990). We decided to assess the value of peroperative radioimmunodetection (PROD) using a specially designed gamma detection probe (yDP). We have also studied the value of measuring monoclonal antibody uptake in excised tissue as an aid to interpreting a frozen section. Patients and methodsSixteen patients having conventional routine radioimmunoscintigraphy prior to surgery for proven or suspected ovarian carcinoma were studied ( and other sites of possible involvement: Radioactivity that might come from ...

show abstract

“…This suggested that cancer associated MUC1 is non-or at least under-glycosylated in comparison with the normal MUC1 glycoprotein. Among the characterized MUC1 antibodies, clone SM3 is renowned for its selectivity against tumor-associated MUC1 (Granowska et al, 1990;Burchell and Taylor-Papadimitriou, 1993;Granowska et al, 1993;Wilkie et al, 2008), we therefore first constructed SM3 scFv-based CAR with IL-12 co-expression (SM3-CAR). Because it has been reported that 4-1BB domain may enhance CAR-T cell persistence, our final version of SM3-CAR contained SM3 scFv fused to sequences derived from CD28, 4-1BB, and CD3, followed by an internal ribosome entry site (IRES)-controlled IL-12 sequence ( Figure 2A).…”

Section: Anti-muc1-car Designmentioning

confidence: 99%

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

You

Jiang

Zhang

et al. 2016

Sci. China Life Sci.

129

View full text Add to dashboard Cite

Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer

Cited by 11 publications

References 19 publications

99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection

99mTc-labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection

Peroperative radioimmunodetection of ovarian carcinoma using a hand-held gamma detection probe

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

Contact Info

Product

Resources

About